Welcome!

News Feed Item

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

LONDON, March 19, 2014 /PRNewswire/ --


Prospects  For  Leading  Players

Vaccine  manufacturing  technology  and  services  -  your  guide  to  trends  and  revenue  prospects  for  vaccine  production

What's the outlook for producing vaccines? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 205 page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2014 to 2024, with growing revenues.

Forecasts  from  2014-2024  and  other  analyses  show  you  commercial  prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of four exclusive expert opinion interviews from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Eluemuno Blyden, CEO and Founder, AfriVax
- Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
- Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
- Dr. Stefan Beyer, Managing Director, Vibalogics

You  will  find  prospects  for  key  submarkets

In addition to analyses of the overall world market, you will see revenue forecasting for these five world-level vaccine submarkets to 2024:
-    Paediatric vaccines
-    Influenza vaccines
-    Adult prophylactic vaccines
-    Therapeutic vaccines
-    Contract vaccine manufacturing

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Which vaccine submarket will generate the most revenues? How will the vaccine contract manufacturing market expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

To see an exec summary of this report please email Sara Peerun on [email protected]

What  are  the  prospects  for  vaccine  contract  manufacturing  in  the  leading  regions  and  countries?

Events and progress worldwide will influence the market, especially outsourced vaccine manufacturing in emerging countries.

In our study you will find individual revenue forecasts to 2024 for 11 vaccine contract manufacturing national markets:
-    US
-    Japan
-    Germany
-    Italy
-    Spain
-    France
-    UK
-    Russia
-    China
-    India
-    Brazil
-    RoW

Many opportunities exist within the vaccines contract manufacturing market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading  companies  and  potential  for  market  growth

Overall world revenue for the vaccines contract manufacturing market will reach $705.62m in 2014, our study forecasts. We predict strong revenue growth from 2014 to 2024. Our research shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
-    Baxter BioPharma Solutions
-    Boehringer Ingelheim
-    Catalent
-    Charles River Laboratories
-    IDT Biologika GmbH
-    Lonza
-    Meridian Life Science
-    Sigma-Aldrich
-    SynCo Bio Partners
-    OSO BioPharmaceuticals Manufacturing

In general, a company profile gives you the following information:
-    Overview of the company
-    Discussion of a company's activities and outlook including descriptions of leading products
-    Recent financial results
-    Assessment of recent developments - mergers and acquisitions (M&A),  new products, and collaborations, inc. alliances, partnerships and joint ventures

To see an exec summary of this report please email Sara Peerun on [email protected]

What  issues  will  affect  the  vaccine  contract  manufacturing  market?

Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:
-    Healthy pipeline of vaccine products
-    Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
-    Pandemic preparedness
-    Pricing, regulation and government policy
-    Perception of risk in outsourcing vaccine manufacturing

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How  the Vaccine  Manufacturing  Technology  and  Services:  World  Market  Forecast  2014-2024:  Prospects  For  Leading  Players  report  helps  you

In summary, our 205 page report gives you the following knowledge:
-    Revenues forecasts to 2024 for the overall world vaccine market and 5 submarkets - discover the industry's prospects, finding promising places for investments and revenues
-    Assessment of  10 leading companies, and others, discovering their activities and outlooks
-    Market forecasting to 2024 for 11 leading national vaccine contract manufacturing markets - USA, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China and RoW
-    View opinions from our survey, seeing 4 interviews with leading authorities
-    Investigation of competition and opportunities influencing sales
-    Discussion of what stimulates and restrains the vaccine contract manufacturing market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information  found  nowhere  else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how our report could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the vaccines market and vaccine contract manufacturing market. You will find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            [email protected] or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1221/Vaccine-Manufacturing-Technology-and-Services-World-Market-Forecast-2014-2024

Companies  Listed  in  this  report:

AAI Pharma Services Corp.
AbbVie
Accugenix
Activaris Biotech
Adamis Pharmaceuticals
Aduro Biotech
Advanced Bioscience Laboratories, Inc.
Advaxis
AFFiRis
Afrivax
Agenus
ALK- Abello
Alpha Biologics
AlphaVax
Althea Technologies, Inc.
Ambiopharm
Amgen
AmProtein
Antigen Express
Antigenics
Aptuit CTS
Argos Therapeutics
Artelis
AstraZeneca
 ATMI
ATMI LifeSciences
AuRx
Avista Capital Partners
Batavia
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer
Bayer Healthcare
Bayhill Therapeutics
Beijing Tiantan Biological Products
Bellicum Pharmaceuticals
Ben Venue Laboratories
Bend Research
Berna Biotech
Bharat Biotech International
Binnopharm
Biofabri
BioKangtai
Biological E. Serum Institute
Biomay
Biondvax
Bionor Pharma
BioReliance
BioSante Pharmaceuticals
Biovest International
Biovian
BN ImmunoTherapeutics
Boehringer Ingelheim
Bosch
Cadila Pharmceuticals
Cancer Advances
Cardinal Health
Catalent
Catalent (Shanghai) Clinical Trial Supplies
Catalent Pharma Solutions
CatScl
Celldex Therapeutics
Cellexus Limited
CEL-SCI
Celtic Pharma
Cerebricon
CG Therapeutics
Charles River Biopharmaceutical Services
Charles River Laboratories
Chengdu Institute of Biological Products
China National Biotech Corporation
Chiron B.V
Circassia
CMC Biologics
Cobra Biologics
Colby Pharmaceutical
Cook Pharmica
Corden Pharma
Covance
Crucell
CSL Biologicals
Cytos Biotechnology
Cytovance Biologics
Daiichi Sankyo
Dalian Hissen Bio-Pharm
DBV Technologies
Dendreon
DSM Biologics
Dynport Vaccine
EMD Serono
Emergent BioSolutions
Endocyte
Etubics
Eurogentec Biologics
FiberCell
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
Galena
Gcon
GE Healthcare Life Sciences
GE Wave Biotech
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar
GenVec
GeoVax
GlaxoSmithKline Biologicals
Gliknik
Globelmmune
Goodwin Biotechnology Inc.
Gradalis
Grand River Aseptic Manufacturing
GSK
Hawaii Biotech
Heat Biologics
Hospira
HTD Biosystems
iBio
IDT Biologika GmbH
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmunsanT
ImVisioN Therapeutics
Innogenetics Biologicals
Inovio Pharmaceuticals
Intercell Corporation
Inviragen
Invitrogen
Irvine Scientific
Janssen Alzheimer Immunotherapy
Japan Vaccine Co
Jennerex
JHP Pharmaceuticals
JN-International Medical
Johnson & Johnson
Jubilant HollisterStier
Kuhner
Leidos
LG Life Sciences
LigoCyte Pharmaceuticals
Liquidia Technologies
Lonza
MabVax Therapeutics
Medicago
MedImmune
Meisser Filtration
Memgen
Merck
Merck Serono
Meridian Life Science
Millipore
Mitsubishi Tanabe Pharma
MorphoSys
MP Biomedicals
NanoBio
Nanotherapeutics
Nascent Biologics
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
Novartis Vaccines and Diagnostics
NovaRX
Novasep
Novavax
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Optimer Biotechnology
Orban Biotech
Organon Teknika Corporation
OSO Biopharmaceuticals Manufacturing
Pall Life Sciences
Pantec
Paragon Bioservices
Patheon
PaxVax
PBS Biotech
Penn Pharma
Pfizer (Wyeth Pharmaceuticals)
Pfrenex
PharmAthene
Philip Morris International
Piedmont Research Center
Pierre-Guérin Biolafitte
Pique Therapeutics
Polynoma
Prima Biomed
ProBioGen
Profectus BioSciences
Protein Sciences Corporation
Rame-Hart Sanovo
Refine Technology
Riemser Pharma GmbH
Roche
SAFC
Sanaria
Sanofi Pasteur
Sanofi Pasteur MSD
Sartorius Stedim Biotech
Selecta Biosciences
Selecta RUS
Shanghai Sunway Biotech
ShangPharma Corporation  
Shantha Biotech
Sigma Aldrich
Soligenix
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Synco Bio Partners
Takeda
TapImmune
TD Vaccines
Theraclone Sciences
Thermo Fisher scientific
Thymon
Transgene
TVAX Biomedical
United Biomedical
Vaccine Technologies
Vaccinogen
Vaxart
VaxInnate
VaxOnco
Vibalogics
Vivalis
Waisman Biomanufacturing
Wave Biotech
Xcellerex
Xencor
ZellWerk
Zhangjiang Biotech & Pharmaceutical Base
Zhejiang Jiang Yuan Tang Biotechnology Corporation

Other Organisations Mentioned in This Report

Aaron Diamond AIDS Research Center
Aeras Global TB Vaccine Foundation
Agência Nacional de Vigilância Sanitária (ANVISA)
Centers for Disease Control and Prevention CDC (US)
Chinese State Food and Drug Administration (SFDA)
Defense Advanced Researched Projects Agency (DAPRA)
Emory University
European Medicines Agency (EMA)
Executive European Commission (European Union)
Health Canada
Hospital Clínic de Barcelona
Infectious Disease Research Institute (IDRI)
International AIDS Vaccine Initiative (IAVI)
Ministry of Industry and Trade (Russia)
Murdoch Childrens Research Institute
National Institute of Health (US)
PATH
Research Foundation for Microbial Diseases of Osaka University
The Department of Health and Human Services (HHS) (US)
The Drug Enforcement Administration (DEA) (US)
The Food and Drug Administration (FDA) (Korean)
The Food and Drug Administration (FDA) (US)
The National Institute of Allergy and Infectious Diseases (NIAID)
The U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)
The United Nation Industrial Development Organisation (UNIDO)
US Naval Medical Research Center
Vaccine Manufacturers Associations (India)
World Health Organisation (WHO)

To see an exec summary of this report please email Sara Peerun on [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
Data-as-a-Service is the complete package for the transformation of raw data into meaningful data assets and the delivery of those data assets. In her session at 18th Cloud Expo, Lakshmi Randall, an industry expert, analyst and strategist, will address: What is DaaS (Data-as-a-Service)? Challenges addressed by DaaS Vendors that are enabling DaaS Architecture options for DaaS
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...
Companies can harness IoT and predictive analytics to sustain business continuity; predict and manage site performance during emergencies; minimize expensive reactive maintenance; and forecast equipment and maintenance budgets and expenditures. Providing cost-effective, uninterrupted service is challenging, particularly for organizations with geographically dispersed operations.
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
DevOps is not just last year’s buzzword. Companies with DevOps practices are 2.5x more likely to exceed profitability, market share, and productivity goals. But how do you enable high performance? What can you do right now to start? Find out from DevOps experts including Gene Kim, co-author of "The Phoenix Project," and the Dynatrace Center of Excellence.
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
SYS-CON Events announced today that Column Technologies will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Established in 1998, Column Technologies is a global technology solutions provider with over 400 employees, headquartered in the United States with offices in Canada, India, and the United Kingdom. Column Technologies provides “Best of Breed” technology solutions that automate the key DevOps principal...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...